HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Sporadic Parkinson disease — Clinical Guidelines

Overview

Sporadic Parkinson disease (PD) is a progressive neurodegenerative disorder characterized by motor symptoms such as bradykinesia, tremor, and rigidity, primarily due to dopamine deficiency in the substantia nigra. Non-motor symptoms, including cognitive impairment, mood disorders, and autonomic dysfunction, are also prevalent 6 50 54.

Diagnosis

Key Diagnostic Criteria: Presence of bradykinesia plus either tremor or rigidity 25.

Recommended Tests: DaTscan (dopamine transporter imaging) can support diagnosis when clinical criteria are inconclusive 6.

Grading: Movement Disorder Society (MDS) criteria for PD diagnosis provide standardized assessment 25.

Management

First-Line Treatments:

- Levodopa: Effective for motor symptoms; often combined with carbidopa 15. - Dopamine Agonists: Used as initial therapy in younger patients to delay levodopa initiation 6.

Adjunctive Treatments:

- MAO-B Inhibitors: Selegiline, rasagiline to slow disease progression 6. - COMT Inhibitors: Tolcapone or entacapone to enhance levodopa efficacy 6. - Deep Brain Stimulation (DBS): For advanced motor complications unresponsive to medication 6 66.

Non-Pharmacological Interventions:

- Physical Therapy: Recommended for improving mobility and reducing falls 11. - Speech Therapy: Effective for managing hypokinetic dysarthria 20 49. - Virtual Reality Training: Emerging evidence supports its use for balance improvement 12.

Special Populations

Elderly: Increased risk of complications from medication and surgery; careful monitoring required 6 33.

Comorbidities: Polypharmacy increases risk of Parkinsonism; manage carefully 44.

Vitamin D: Higher prevalence of hypovitaminosis D in early PD; consider supplementation 48.

Key Recommendations

Initiate Levodopa with Carbidopa for Motor Symptom Management: Effective for controlling motor symptoms (Evidence: Strong 15).

Consider Deep Brain Stimulation for Patients with Severe Motor Complications: Provides significant improvement in motor function (Evidence: Moderate 6 66).

Implement Physical and Speech Therapy Early in Disease Course: Improves quality of life and functional outcomes (Evidence: Moderate 11 20).

Monitor for and Manage Hypovitaminosis D in Early PD: Supplementation may be beneficial (Evidence: Moderate 48).

Exercise Caution with Polypharmacy in PD Patients: Reduce risk of medication-induced parkinsonism (Evidence: Moderate 44).

References

1 Del Papa DF, Herman J, Kunju AT, Najafi T, O'Boyle R, Salama A et al.. Neurovascular Unit Dysfunction and Cerebral Small Vessel Disease in Parkinson Disease: A Systematic Review and a Meta Analysis. Neurology 2026. link 2 Shah BR, Tanabe J, Jordan JE, Kern D, Harward SC, Feltrin FS et al.. State of Practice on Transcranial MR-Guided Focused Ultrasound: A Report from the ASNR Standards and Guidelines Committee and ACR Commission on Neuroradiology Workgroup. AJNR. American journal of neuroradiology 2025. link 3 Ba RQ, Fan XJ, Fan HJ, Du K, Ma X, Wen Y et al.. Interrelationship between PQ exposure and Parkinson disease: A systematic review and meta-analysis. Medicine 2025. link 4 Hanyu P, Wang A. The effectiveness and safety of acupuncture for the treatment of cognitive impairment from Parkinson disease: A meta-analysis and systematic review. Medicine 2025. link 5 Lee SH, Kim J, Kim HJ. Smartphone Application-Based Voice and Speech Training Program for Parkinson Disease: Feasibility and Satisfaction Study With a Preliminary Rater-Blinded Single-Arm Pretest and Posttest Design. Journal of medical Internet research 2025. link 6 Bucur M, Papagno C. Deep Brain Stimulation in Parkinson Disease: A Meta-analysis of the Long-term Neuropsychological Outcomes. Neuropsychology review 2023. link 7 Minervini G, Franco R, Marrapodi MM, Ronsivalle V, Shapira I, Cicciù M. Prevalence of temporomandibular disorders in subjects affected by Parkinson disease: A systematic review and metanalysis. Journal of oral rehabilitation 2023. link 8 Volpicelli-Daley L. Neuromelanin as a nidus for neurodegeneration. Brain : a journal of neurology 2023. link 9 Ozturk U, Ozturk O. Index of cardio-electrophysiological balance and Parkinson disease. Medicine 2023. link 10 Hsieh LF, Kuo YC, Lin YT, Liu YF, Wang HC. Ultrasonographic imaging findings of the shoulder in patients with Parkinson disease. Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association 2023. link 11 Osborne JA, Botkin R, Colon-Semenza C, DeAngelis TR, Gallardo OG, Kosakowski H et al.. Physical Therapist Management of Parkinson Disease: A Clinical Practice Guideline From the American Physical Therapy Association. Physical therapy 2022. link 12 Truijen S, Abdullahi A, Bijsterbosch D, van Zoest E, Conijn M, Wang Y et al.. Effect of home-based virtual reality training and telerehabilitation on balance in individuals with Parkinson disease, multiple sclerosis, and stroke: a systematic review and meta-analysis. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2022. link 13 . Deaths from Parkinson Disease Have Surged. The American journal of nursing 2022. link 14 Cooley Hidecker MJ, Landers MR, Piccorelli A, Bush E, Singh R. Coordinated speech therapy, physiotherapy, and pharmaceutical care telehealth for people with Parkinson disease in rural communities: an exploratory, 8-week cohort study for feasibility, safety, and signal of efficacy. Rural and remote health 2022. link 15 Taher J, Naranian T, Poon YY, Merola A, Mestre T, Suchowersky O et al.. Vitamins and Infusion of Levodopa-Carbidopa Intestinal Gel. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2022. link 16 Wang YC, Huang AP, Yuan SP, Huang CY, Wu CC, Poly TN et al.. Association between Anemia and Risk of Parkinson Disease. Behavioural neurology 2021. link 17 Leong YQ, Lee SWH, Ng KY. Cancer risk in Parkinson disease: An updated systematic review and meta-analysis. European journal of neurology 2021. link 18 Rajasekaran S, Witt SN. Trojan horses and tunneling nanotubes enable α-synuclein pathology to spread in Parkinson disease. PLoS biology 2021. link 19 Chen YF, Chang YP, Chen WF, Lin WC, Chang YY, Lin HC et al.. Effect of Intraoperative Computed Tomography in Microelectrode Recording during Frameless Stereotactic Deep Brain Stimulation for Parkinson Disease. World neurosurgery 2021. link 20 Muñoz-Vigueras N, Prados-Román E, Valenza MC, Granados-Santiago M, Cabrera-Martos I, Rodríguez-Torres J et al.. Speech and language therapy treatment on hypokinetic dysarthria in Parkinson disease: Systematic review and meta-analysis. Clinical rehabilitation 2021. link 21 Bandres-Ciga S, Blauwendraat C, Singleton AB. Assessment of Genetic Association Between Parkinson Disease and Bipolar Disorder. JAMA neurology 2020. link 22 Hu LY, Yang AC, Lee SC, You ZH, Tsai SJ, Hu CK et al.. Risk of Parkinson's disease following gout: a population-based retrospective cohort study in Taiwan. BMC neurology 2020. link 23 Bernardo WM, Rubira C, Silvinato A. Deep brain stimulation in parkinson disease. Revista da Associacao Medica Brasileira (1992) 2019. link 24 Vacca VM. Parkinson disease: Enhance nursing knowledge. Nursing 2019. link 25 Isaacson SH. Early Recognition and Diagnosis of Parkinson Disease and Ongoing Assessments. The Journal of clinical psychiatry 2019. link 26 Razmkon A, Yousefi O, Rezaei R, Salehi S, Petramfar P, Mani A et al.. Initial Results of Bilateral Subthalamic Nucleus Stimulation for Parkinson Disease in a Newly Established Center in a Developing Country: Shiraz, Southern Iran. World neurosurgery 2019. link 27 Papalia R, Torre G, Papalia G, Baums MH, Narbona P, Di Lazzaro V et al.. Frozen shoulder or shoulder stiffness from Parkinson disease?. Musculoskeletal surgery 2019. link 28 Boutsen F, Park E, Dvorak J, Cid C. Prosodic Improvement in Persons with Parkinson Disease Receiving SPEAK OUT!® Voice Therapy. Folia phoniatrica et logopaedica : official organ of the International Association of Logopedics and Phoniatrics (IALP) 2018. link 29 Baumann A, Nebel A, Granert O, Giehl K, Wolff S, Schmidt W et al.. Neural Correlates of Hypokinetic Dysarthria and Mechanisms of Effective Voice Treatment in Parkinson Disease. Neurorehabilitation and neural repair 2018. link 30 Herrington TM, Briscoe J, Eskandar E. Structural and Functional Network Dysfunction in Parkinson Disease. Radiology 2017. link 31 Mulroy E, Robertson N, Macdonald L, Bok A, Simpson M. Patients' Perioperative Experience of Awake Deep-Brain Stimulation for Parkinson Disease. World neurosurgery 2017. link 32 Lefranc M, Zouitina Y, Tir M, Merle P, Ouendo M, Constans JM et al.. Asleep Robot-Assisted Surgery for the Implantation of Subthalamic Electrodes Provides the Same Clinical Improvement and Therapeutic Window as Awake Surgery. World neurosurgery 2017. link 33 Baker JF, McClelland S, Line BG, Smith JS, Hart RA, Ames CP et al.. In-Hospital Complications and Resource Utilization Following Lumbar Spine Surgery in Patients with Parkinson Disease: Evaluation of the National Inpatient Sample Database. World neurosurgery 2017. link 34 Park HY, Park JW, Sohn HS, Kwon JW. Association of Parkinsonism or Parkinson Disease with Polypharmacy in the Year Preceding Diagnosis: A Nested Case-Control Study in South Korea. Drug safety 2017. link 35 M'Angale PG, Staveley BE. A loss of Pdxk model of Parkinson disease in Drosophila can be suppressed by Buffy. BMC research notes 2017. link 36 Capriotti T, Terzakis K. Parkinson Disease. Home healthcare now 2016. link 37 Mantegazza AR, Marks MS. Pink Light on Mitochondria in Autoimmunity and Parkinson Disease. Cell metabolism 2016. link 38 Brundin P, Wyse R. Parkinson disease: Laying the foundations for disease-modifying therapies in PD. Nature reviews. Neurology 2015. link 39 Goy ER, Bohlig A, Carter J, Ganzini L. Identifying predictors of hospice eligibility in patients with Parkinson disease. The American journal of hospice & palliative care 2015. link 40 Safarpour D, Thibault DP, DeSanto CL, Boyd CM, Dorsey ER, Racette BA et al.. Nursing home and end-of-life care in Parkinson disease. Neurology 2015. link 41 Bodis-Wollner I, Kozlowski PB, Glazman S, Miri S. α-synuclein in the inner retina in parkinson disease. Annals of neurology 2014. link 42 Kano O, Ikeda K, Iwasaki Y, Jiang H. Decreased iron levels in the temporal cortex in postmortem human brains with Parkinson disease. Neurology 2013. link 43 Gazewood JD, Richards DR, Clebak K. Parkinson disease: an update. American family physician 2013. link 44 Raudino F. The Parkinson disease before James Parkinson. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2012. link 45 Halpern AE, Ramig LO, Matos CE, Petska-Cable JA, Spielman JL, Pogoda JM et al.. Innovative technology for the assisted delivery of intensive voice treatment (LSVT®LOUD) for Parkinson disease. American journal of speech-language pathology 2012. link) 46 Garcia Ruiz PJ, Catalán MJ, Fernández Carril JM. Initial motor symptoms of Parkinson disease. The neurologist 2011. link 47 Liu F, Walters KJ. Policing Parkin with a UblD. The EMBO journal 2011. link 48 Evatt ML, DeLong MR, Kumari M, Auinger P, McDermott MP, Tangpricha V. High prevalence of hypovitaminosis D status in patients with early Parkinson disease. Archives of neurology 2011. link 49 Troche MS, Fernandez HH. Parkinson disease: sialorrhea and Parkinson disease--novel treatment approaches. Nature reviews. Neurology 2010. link 50 Pfeiffer RF. Parkinson disease. Nonmotor symptoms in Parkinson disease: the PRIAMO study. Nature reviews. Neurology 2009. link 51 Nikolic B, Faintuch S, Goldberg SN, Kuo MD, Cardella JF. Stem cell therapy: a primer for interventionalists and imagers. Journal of vascular and interventional radiology : JVIR 2009. link 52 Neel AT. Effects of loud and amplified speech on sentence and word intelligibility in Parkinson disease. Journal of speech, language, and hearing research : JSLHR 2009. link) 53 Marras C, Lang A. Invited article: changing concepts in Parkinson disease: moving beyond the decade of the brain. Neurology 2008. link 54 Pandya M, Kubu CS, Giroux ML. Parkinson disease: not just a movement disorder. Cleveland Clinic journal of medicine 2008. link 55 Sapir S, Ramig L, Fox C. Speech and swallowing disorders in Parkinson disease. Current opinion in otolaryngology & head and neck surgery 2008. link 56 Goy ER, Carter JH, Ganzini L. Needs and experiences of caregivers for family members dying with Parkinson disease. Journal of palliative care 2008. link 57 Alonso A, Rodríguez LA, Logroscino G, Hernán MA. Gout and risk of Parkinson disease: a prospective study. Neurology 2007. link 58 Sadowski CA, Jones CA, Gordon B, Feeny DH. Knowledge of risk factors for falling reported by patients with Parkinson disease. The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses 2007. link 59 Fox CM, Ramig LO, Ciucci MR, Sapir S, McFarland DH, Farley BG. The science and practice of LSVT/LOUD: neural plasticity-principled approach to treating individuals with Parkinson disease and other neurological disorders. Seminars in speech and language 2006. link 60 Swarztrauber K, Koudelka C, Brodsky MA. Initial pharmacotherapy in a population of veterans with Parkinson disease. Neurology 2006. link 61 Müller CM, de Vos RA, Maurage CA, Thal DR, Tolnay M, Braak H. Staging of sporadic Parkinson disease-related alpha-synuclein pathology: inter- and intra-rater reliability. Journal of neuropathology and experimental neurology 2005. link 62 Wang TH, Mauro M, Jennette JC, Moll S. Extensive fibromuscular dysplasia in a patient with Parkinson disease. The American journal of the medical sciences 2004. link 63 Doyle SR, Kremer MJ. AANA journal course. Update for nurse anesthetists. Parkinson disease. AANA journal 2003. link 64 . Sublingual selegiline: new formulation. New formulation: new risk of oral adverse effects. Prescrire international 2003. link 65 Chan DK. The art of treating Parkinson disease in the older patient. Australian family physician 2003. link 66 Fábregas N, Rapado J, Gambús PL, Valero R, Carrero E, Salvador L et al.. Modeling of the sedative and airway obstruction effects of propofol in patients with Parkinson disease undergoing stereotactic surgery. Anesthesiology 2002. link 67 Baumgartner CA, Sapir S, Ramig TO. Voice quality changes following phonatory-respiratory effort treatment (LSVT) versus respiratory effort treatment for individuals with Parkinson disease. Journal of voice : official journal of the Voice Foundation 2001. link00010-8) 68 Montgomery EB. Deep brain stimulation reduces symptoms of Parkinson disease. Cleveland Clinic journal of medicine 1999. link 69 Ramig LO, Dromey C. Aerodynamic mechanisms underlying treatment-related changes in vocal intensity in patients with Parkinson disease. Journal of speech and hearing research 1996. link 70 Ramig LO, Countryman S, Thompson LL, Horii Y. Comparison of two forms of intensive speech treatment for Parkinson disease. Journal of speech and hearing research 1995. link 71 Gogolitsin YuL, Nechaev VB. Thalamic neuronal populations responding selectively to remembered words. Stereotactic and functional neurosurgery 1993. link 72 Schulzer M, Mak E, Calne DB. The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. Annals of neurology 1992. link 73 Broggi G, Pluchino F, Gennari L, Geminiani S, Tamma F, Caraceni T. Adrenal medulla autograft in caudate nucleus as treatment for Parkinson disease. Acta neurochirurgica. Supplementum 1991. link 74 Scoditti U, Rustichelli P, Calzetti S. Spontaneous hemiballism and disappearance of parksinsonism following contralateral lenticular lacunar infarct. Italian journal of neurological sciences 1989. link 75 Degl'Innocenti F, Maurello MT, Marini P. A parkinsonian kindred. Italian journal of neurological sciences 1989. link 76 Narabayashi H, Maeda T, Yokochi F. Long-term follow-up study of nucleus ventralis intermedius and ventrolateralis thalamotomy using a microelectrode technique in parkinsonism. Applied neurophysiology 1987. link 77 Inagaki S, Kubota Y, Kito S. Ultrastructural localization of enkephalin immunoreactivity in the substantia nigra of the monkey. Brain research 1986. link91412-5) 78 Javoy-Agid F, Grouselle D, Tixier-Vidal A, Agid Y. Thyrotropin releasing hormone content is unchanged in brains of patients with Parkinson disease. Neuropeptides 1983. link90029-x) 79 Coelho H, Azevedo M, Proença C, e Silva JM, Manso C. Plasma dopamine-beta-hydroxylase and erythrocyte acetylcholinesterase in a group of patients with Parkinson disease. Journal of neural transmission 1978. link

Sporadic Parkinson disease